{"id":"NCT01646021","sponsor":"Janssen Research & Development, LLC","briefTitle":"Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy","officialTitle":"A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12-10","primaryCompletion":"2015-06-05","completion":"2016-12-15","firstPosted":"2012-07-20","resultsPosted":"2017-03-01","lastUpdate":"2018-01-19"},"enrollment":280,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Mantle Cell Lymphoma"],"interventions":[{"type":"DRUG","name":"Ibrutinib","otherNames":[]},{"type":"DRUG","name":"Temsirolimus","otherNames":[]}],"arms":[{"label":"Ibrutinib","type":"EXPERIMENTAL"},{"label":"Temsirolimus","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma who received at least 1 prior chemotherapy regimen.","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"Time from the date of randomization until the date of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death, whichever occurred first (approximately 48 months)","effectByArm":[{"arm":"Ibrutinib","deltaMin":15.6,"sd":null},{"arm":"Temsirolimus","deltaMin":6.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":12},"locations":{"siteCount":92,"countries":["Belgium","Brazil","Canada","Chile","Colombia","Czechia","France","Germany","Hungary","Ireland","Mexico","Netherlands","Poland","Portugal","Russia","South Korea","Spain","Sweden","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["28751558","26673811"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":79,"n":139},"commonTop":["Thrombocytopenia","Diarrhoea","Anaemia","Fatigue","Cough"]}}